Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's average Revenue per Share Growth Rate was 9.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM was 12.50% per year. The lowest was 3.90% per year. And the median was 11.80% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM 3-Year Revenue Growth Rate Related Terms
CAS:PRO vs ZTS, UTHR, VTRS: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 11.60% mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a 3-Year Revenue Growth Rate of 11.60% as of Dec. 2025. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. This is near median its historical median of 11.80. Over the past decade, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's 3-Year Revenue Growth Rate has ranged from 3.90 to 12.50. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #216 out of 905 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's 3-Year Revenue Growth Rate too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current 3-Year Revenue Growth Rate of 11.60% is near median its 10-year median of 11.80. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 12.50. The Drug Manufacturers industry median 3-Year Revenue Growth Rate is 3.70. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 11.60% is 213.5% above this industry median. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #216 out of 905 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's 3-Year Revenue Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #216 out of 905 companies for 3-Year Revenue Growth Rate. This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 3.70. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's value of 11.60% is 213.5% above this benchmark. Historically, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's own 3-Year Revenue Growth Rate has ranged from 3.90 to 12.50 over the past decade. While the company's 10-year median is 11.80 vs. the industry median of 3.70, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current 3-Year Revenue Growth Rate of 11.60% is 213.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current 3-Year Revenue Growth Rate is 11.60%, which is near median its own 10-year median of 11.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,359.29, compared to a current price of MAD1,379.00 — trading 1.5% above its estimated fair value. The current 3-Year Revenue Growth Rate is 11.60%, which is near median its 10-year median of 11.80 and 213.5% above the Drug Manufacturers industry median of 3.70. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current 3-Year Revenue Growth Rate is 11.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,379.00 is trading 1.5% above its estimated GF Value™ of MAD1,359.29.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
3-Year Revenue Growth Rate: 11.60% (near median its 10-year median of 11.80)
GF Value™: MAD1,359.29 vs. price of MAD1,379.00 (1.5% above fair value)
Industry Position: 213.5% above the Drug Manufacturers median (#216 of 905)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score
Get the complete analysis for CAS:PRO
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
